Rangel-Pozzo Aline, Yu Pak Lok Ivan, LaL Sadhana, Asbaghi Yasmin, Sisdelli Luiza, Tammur Pille, Tamm Anu, Punab Mari, Klewes Ludger, Louis Sherif, Knecht Hans, Olujohungbe Adebayo, Mai Sabine
Cell Biology, Research Institute of Oncology and Hematology, University of Manitoba, CancerCare Manitoba, Winnipeg, MB R3C 2B1, Canada.
Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Cancers (Basel). 2021 Apr 19;13(8):1969. doi: 10.3390/cancers13081969.
The prognosis of multiple myeloma (MM), an incurable B-cell malignancy, has significantly improved through the introduction of novel therapeutic modalities. Myeloma prognosis is essentially determined by cytogenetics, both at diagnosis and at disease progression. However, for a large cohort of patients, cytogenetic analysis is not always available. In addition, myeloma patients with favorable cytogenetics can display an aggressive clinical course. Therefore, it is necessary to develop additional prognostic and predictive markers for this disease to allow for patient risk stratification and personalized clinical decision-making. Genomic instability is a prominent characteristic in MM, and we have previously shown that the three-dimensional (3D) nuclear organization of telomeres is a marker of both genomic instability and genetic heterogeneity in myeloma. In this study, we compared in a longitudinal prospective study blindly the 3D telomeric profiles from bone marrow samples of 214 initially treatment-naïve patients with either monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or MM, with a minimum follow-up of 5 years. Here, we report distinctive 3D telomeric profiles correlating with disease aggressiveness and patient response to treatment in MM patients, and also distinctive 3D telomeric profiles for disease progression in smoldering multiple myeloma patients. In particular, lower average intensity (telomere length, below 13,500 arbitrary units) and increased number of telomere aggregates are associated with shorter survival and could be used as a prognostic factor to identify high-risk SMM and MM patients.
多发性骨髓瘤(MM)是一种无法治愈的B细胞恶性肿瘤,通过引入新的治疗方式,其预后有了显著改善。骨髓瘤的预后基本上由细胞遗传学决定,无论是在诊断时还是疾病进展时。然而,对于大量患者群体来说,细胞遗传学分析并非总是可行。此外,细胞遗传学特征良好的骨髓瘤患者可能表现出侵袭性的临床病程。因此,有必要为这种疾病开发更多的预后和预测标志物,以便对患者进行风险分层并做出个性化的临床决策。基因组不稳定是骨髓瘤的一个突出特征,我们之前已经表明,端粒的三维(3D)核组织是骨髓瘤基因组不稳定和遗传异质性的一个标志物。在这项研究中,我们在一项纵向前瞻性研究中,对214例初始未经治疗的意义未明的单克隆丙种球蛋白病(MGUS)、冒烟型多发性骨髓瘤(SMM)或MM患者的骨髓样本的3D端粒图谱进行了盲法比较,这些患者的最短随访时间为5年。在此,我们报告了与MM患者疾病侵袭性和患者对治疗的反应相关的独特3D端粒图谱,以及冒烟型多发性骨髓瘤患者疾病进展的独特3D端粒图谱。特别是,较低的平均强度(端粒长度,低于13500任意单位)和端粒聚集体数量增加与较短的生存期相关,可作为识别高危SMM和MM患者的预后因素。